Expert Review of Hematology最新文献_第2页

Revolutionizing hypertension treatment: aprocitentan's dual action against resistant hypertension. 革命性的高血压治疗：阿普昔坦对顽固性高血压的双重作用。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-05-02 DOI: 10.1080/17474086.2025.2500607

Amirhossein Sahebkar, Ali H Eid

引用次数: 0

How can we improve healthcare outcomes for hemophilia B patients with inhibitors? 我们如何改善使用抑制剂的B型血友病患者的医疗结果？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-29 DOI: 10.1080/17474086.2025.2499524

Kristin N Maher, Allison P Wheeler

引用次数: 0

Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control trial. 肌筋膜疗法（MFT）联合传统物理疗法和间歇性预防对血友病关节健康短期改善的有效性：一项随机对照试验

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-25 DOI: 10.1080/17474086.2025.2495674

Mridul Makkar, Mullai S Dhinakaran, Prateek Shukla, Diksha Sarwan, Soumya Ojha, M Joseph John

{"title":"Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control trial.","authors":"Mridul Makkar, Mullai S Dhinakaran, Prateek Shukla, Diksha Sarwan, Soumya Ojha, M Joseph John","doi":"10.1080/17474086.2025.2495674","DOIUrl":"https://doi.org/10.1080/17474086.2025.2495674","url":null,"abstract":"Background: Myofascial therapy (MFT) works on biomechanical soft tissue loading principles aimed to reduce pain, improve tissue mobility and function.Aim: To find effectiveness of MFT and traditional physiotherapy with intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy.Research design and methods: Thirty-one patients with Hemophilia A and joint arthropathy (elbows and/or knees) were randomly divided into MFT group (MFT + traditional physiotherapy) and control group (traditional physiotherapy). Both groups received four physiotherapy sessions per week for three weeks and FVIII prophylaxis twice weekly. Haemophilia Joint Health Score (HJHS), Functional Independence Scoring for Haemophilia (FISH), and Range of Motion (ROM) were assessed on Day 0, 10, 21.Results: MFT group demonstrated a significant improvement in their overall HJHS scores (p = 0.016, d = 0.93) and HJHS knee joint scores (p = 0.007, d = 0.57) compared to control group participants. ROM increased substantially in MFT group relative to control group (18.97%; 10.10% improvement in knee and elbow ROM, respectively, vs 9.49%; 1.25%). There was an improvement in FISH scores in both groups, with a slightly greater improvement in control group (13.68% vs 11.08%).Conclusions: MFT is effective and feasible in short-term improvement of joint health in Hemophilia A patients with elbow and knee arthropathy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload. 儿童和青少年镰状细胞病患者的血管病变：与膜联蛋白A1、维生素D和心肌铁超载的串扰

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-18 DOI: 10.1080/17474086.2025.2495670

Mohsen Saleh ElAlfy, Eman Abdel Rahman Ismail, Sara Mostafa Makkeyah, Ahmed Samir, Dina Husseiny Salama, Nanis Mohammed Salah Eldin, Dina Mohamed Fathy ElMaghraby, Nada Ayman Gad, Marwa Fath Ahmed Ali, Fatma Soliman Elsayed Ebeid

{"title":"Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload.","authors":"Mohsen Saleh ElAlfy, Eman Abdel Rahman Ismail, Sara Mostafa Makkeyah, Ahmed Samir, Dina Husseiny Salama, Nanis Mohammed Salah Eldin, Dina Mohamed Fathy ElMaghraby, Nada Ayman Gad, Marwa Fath Ahmed Ali, Fatma Soliman Elsayed Ebeid","doi":"10.1080/17474086.2025.2495670","DOIUrl":"https://doi.org/10.1080/17474086.2025.2495670","url":null,"abstract":"Background: Annexin A1 plays an important role in myocardial defense against ischemia-reperfusion injury. We aimed to evaluate the role of annexin A1 as a potential marker of vasculopathy in children and adolescents with sickle cell disease (SCD) and its relation to myocardial iron content (MIC) and vitamin D status.Research design and methods: Forty-one patients with SCD were compared with 40 age- and sex-matched healthy controls, and underwent assessment of serum annexin A1, vitamin D, Doppler echocardiography and cardiac magnetic resonance (CMR).Results: Six (14.6%) SCD patients had cardiac disease, five (12.2%) had abnormal MIC (≥1.16) and 10 (24.4%) had pulmonary hypertension risk. Annexin A1 levels were significantly lower among patients with SCD compared with healthy controls (p < 0.001). SCD patients with pulmonary hypertension risk, evidence of diastolic dysfunction, and nephropathy as well as those with serum ferritin ≥ 2500 µg/L and vitamin D deficiency had lower Annexin A1 levels than those without. Serum annexin A1 levels were negatively correlated to urinary albumin creatinine ratio (UACR) and Tei index while positively correlated to vitamin D among SCD patients.Conclusions: Annexin A1 could be a promising marker of vasculopathy and may provide a biochemical explanation for vitamin D deficiency in SCD.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correlation between hematocrit and the risk of common human cancers: results of a 1999-2020 observational survey and Mendelian randomization analysis. 红细胞压积与人类常见癌症风险的关系：来自1999-2020年观察性调查和孟德尔随机化分析的结果

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-03 DOI: 10.1080/17474086.2025.2486381

Guo-Sheng Li, Tao Huang, Jing-Xiao Li, Jun Liu, Xiang Gao, Guan-Qiang Yan, Nuo Yang, Hua-Fu Zhou

{"title":"Correlation between hematocrit and the risk of common human cancers: results of a 1999-2020 observational survey and Mendelian randomization analysis.","authors":"Guo-Sheng Li, Tao Huang, Jing-Xiao Li, Jun Liu, Xiang Gao, Guan-Qiang Yan, Nuo Yang, Hua-Fu Zhou","doi":"10.1080/17474086.2025.2486381","DOIUrl":"10.1080/17474086.2025.2486381","url":null,"abstract":"Background: Previous studies have underscored the significance of hematocrit (HCT) in different tumors. However, further research is needed to explore its causal relationship with various tumors.Research design and methods: A retrospective analysis and a Mendelian randomization analysis were conducted on a sample of 3,580,275 samples to investigate the causal relationships between high HCT levels and the risks of developing the 15 prevalent malignant tumors. Additionally, using an in-house cohort, Kaplan-Meier curves were utilized to examine the relationship between HCT levels and the prognosis of patients with prostate cancer (PCa).Results: An elevated HCT level was identified as a protective factor against six types of cancers, including PCa (odds ratio [OR] < 1.000, p < 0.05), and a risk factor for cervical cancer, melanoma, and non-melanoma skin cancer (OR > 1.000, p < 0.05). A potential causal association was found between high HCT levels and decreased risks of developing PCa (OR = 0.887, p < 0.05) and breast cancer (OR = 0.893, p < 0.05). HCT was identified as a protective factor against PCa (p < 0.05).Conclusions: This study identified significant associations between HCT and nine tumors. HCT levels may serve as a protective factor against PCa.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"333-344"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices. 美国社区肿瘤学实践中急性髓系白血病（AML）患者glasdegib或venetoclax治疗结果的真实世界（RW）研究。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-20 DOI: 10.1080/17474086.2025.2492886

Kristin M Zimmerman Savill, Jonathan K Kish, Choo Hyung Lee, Prathamesh Pathak, Paul D'Amico, Alexander Russell-Smith, Ajeet Gajra

{"title":"Real-world (RW) study of outcomes for acute myeloid leukemia (AML) patients treated with glasdegib or venetoclax in US community oncology practices.","authors":"Kristin M Zimmerman Savill, Jonathan K Kish, Choo Hyung Lee, Prathamesh Pathak, Paul D'Amico, Alexander Russell-Smith, Ajeet Gajra","doi":"10.1080/17474086.2025.2492886","DOIUrl":"10.1080/17474086.2025.2492886","url":null,"abstract":"Background: Glasdegib (GLAS) and venetoclax (VEN) are approved in the US for treating AML in patients aged 75+ or with comorbidities precluding intensive induction chemotherapy. Community oncology outcomes for these therapies are limited.Research design and methods: This retrospective chart review summarized characteristics, treatment patterns, and outcomes of US patients treated with first-line (1 L) GLAS or VEN for AML using descriptive statistics. The study was not designed or powered to compare GLAS and VEN cohorts.Results: Among 50 patients receiving 1 L GLAS (82.0% with low-dose cytarabine), 50.0% achieved complete remission (CR), morphological leukemia-free state (MLFS), or partial response (PR). Median overall survival (OS) was 6.9 months (95% CI: 5.4-8.9). A trial-matched GLAS cohort represented 80.0% of all GLAS-treated patients in the study. Among 83 patients receiving 1 L VEN (94.0% with a hypomethylating agent), 51.8% achieved CR, MLFS, or PR, median OS was 8.4 months (95% CI: 5.7-16.2), and 31.3% met pivotal trial eligibility criteria.Conclusions: This observational study supports the clinical benefit of GLAS and VEN in treating AML patients in the real-world setting.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"399-407"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictors of progression to chronicity in newly diagnosed primary immune thrombocytopenia: a retrospective multicenter French study. 新诊断的原发性免疫性血小板减少症进展为慢性的预测因素：一项法国多中心回顾性研究。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-24 DOI: 10.1080/17474086.2025.2495669

Louise Damian, Vincent Langlois, Fabrice Jardin, Jean-Marc Kerleau, Maximilien Grall, Hervé Levesque, Ygal Benhamou, Gaëtan Sauvetre

{"title":"Predictors of progression to chronicity in newly diagnosed primary immune thrombocytopenia: a retrospective multicenter French study.","authors":"Louise Damian, Vincent Langlois, Fabrice Jardin, Jean-Marc Kerleau, Maximilien Grall, Hervé Levesque, Ygal Benhamou, Gaëtan Sauvetre","doi":"10.1080/17474086.2025.2495669","DOIUrl":"10.1080/17474086.2025.2495669","url":null,"abstract":"Background: The long-term outcome of primary immune thrombocytopenia (ITP) is unpredictable. Chronic ITP is common in adults, requiring second-line treatments with increased morbidity and mortality. Our study aimed to identify predictive factors of chronicity at the time of diagnosis in primary adult ITP.Research design and methods: This retrospective multicenter study included adult patients newly diagnosed with primary ITP. Patients with a normal platelet count and no ongoing medication twelve months after disease onset were categorized in the complete remission ITP group, otherwise in the chronic ITP group.Results: 219 patients were included, 110 in the complete remission ITP group and 109 in the chronic ITP group. In multivariate analysis, predictive factors of progression to chronicity included the absence of an infectious event preceding ITP onset (p = 0.048), the absence of bleeding manifestations (p = 0.002) and a platelet count >10 x 109/L at disease onset (p = 0.02). A poor response to initial corticosteroid treatment was also associated with chronicity, including corticosteroid dependence (p<0.001) and corticosteroid resistance (p = 0.001).Conclusions: In this retrospective French cohort, predictors of chronicity in newly diagnosed primary adult ITP included the absence of preceding infectious event, platelet >10 x 109/L and absence of bleeding manifestations at onset.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"409-415"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions. 靶向CD30治疗淋巴瘤的进展：历史展望和未来方向。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-05-11 DOI: 10.1080/17474086.2025.2492936

Hongju Zhang, Yuting Yan, Shuhua Yi, Qi Sun

{"title":"Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions.","authors":"Hongju Zhang, Yuting Yan, Shuhua Yi, Qi Sun","doi":"10.1080/17474086.2025.2492936","DOIUrl":"10.1080/17474086.2025.2492936","url":null,"abstract":"Introduction: CD30 is a transmembrane protein of the tumor necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms, including classical Hodgkin lymphoma and many non-Hodgkin lymphomas in both pediatric and adult populations.Areas covered: This review delves into the significance of CD30 as a therapeutic target and a prognostic indicator for various lymphomas. It provides a comprehensive overview of anti-CD30 therapeutic interventions developed to date, offering insights into the future direction of lymphoma treatment research. Literature search was conducted from January 1987 to December 2024 using PubMed, Scopus, and Web of Science databases to identify relevant studies.Expert opinion: CD30 has emerged as a critical marker of diagnosis, prognosis, and therapeutic strategies of lymphomas. The introduction of brentuximab vedotin (BV) (Adcetris), an antibody-drug conjugate targeting CD30, has significantly advanced the treatment landscape for multiple lymphoma types, demonstrating enhanced efficacy and manageable safety profiles in CD30+ lymphomas patients. However, drug resistance is observed in few patients. Concurrently, innovative therapeutic strategies targeting CD30, such as chimeric antigen receptor T-cells therapies and bispecific antibodies, are in development. This underscores a strong and ongoing research effort aimed at improving the management of patients with CD30+ lymphomas.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"373-386"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients? 在输血依赖型地中海贫血患者中，磁共振成像监测不同器官铁水平的重要性是什么？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-03-31 DOI: 10.1080/17474086.2025.2486379

Antonella Meloni, Vincenzo Positano, Paolo Ricchi, Alessia Pepe, Riccardo Cau

{"title":"What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?","authors":"Antonella Meloni, Vincenzo Positano, Paolo Ricchi, Alessia Pepe, Riccardo Cau","doi":"10.1080/17474086.2025.2486379","DOIUrl":"10.1080/17474086.2025.2486379","url":null,"abstract":"Introduction: Iron overload is the main pathophysiological driver of organ damage in transfusion-dependent thalassemia (TDT). Magnetic resonance imaging (MRI) provides detailed insights into the distribution and severity of iron accumulation in the different organs.Areas covered: This special report describes the impact of MRI on clinical and therapeutic management and short- and long-term outcomes in TDT patients. PubMed, Scopus, and Google Scholar databases were searched to identify the relevant studies published before November 2024.Expert opinion: Cardiac and hepatic MRI are now well-established modalities, integrated into the clinical practice. They have become essential for tailoring iron chelation therapies to the specific patient's needs and for monitoring treatment efficacy. The improved control of cardiac iron burden has translated into reduced morbidity and mortality. The MRI accessibility remains limited in resource-limited settings and progress in this field relies on educating and training centers to ensure accurate execution and interpretation. The clinicopathological significance, prognostic value, and reproducibility of pancreatic iron levels assessment have been established, charting a path toward its clinical use. There are limited data about renal, adrenal, and pituitary iron deposition, and more research is needed to fully establish the functional significance and to standardize and validate the MRI protocols.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"291-299"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Five decades of successive establishment of hemophilia care in Thailand. 在泰国连续50年建立血友病护理。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2025-04-01 Epub Date: 2025-04-02 DOI: 10.1080/17474086.2025.2486378

Ampaiwan Chuansumrit, Thip Sriphaisal, Triroj Krutvecho, Nongnuch Sirachainan, Pimpun Kitpoka, Monratta Pitakcharoen, Suphaneewan Jaovisidha, Panyu Panburana, Monthon Suwannuraks, Nantana Sri-Udomporn, Chusak Kijkunasathian, Rungrote Nateserinilkul, Bunchoo Pongtanakul, Chanchai Traivaree, Patcharee Komvilaisak, Darintr Sosothikul, Yujinda Lektrakul, Thunyakorn Nuntiyagul, Pacharapan Surapolchai, Natsaruth Songthawee, Ekawat Suwantaroj, Pantep Angchaisuksiri, Theera Ruchutrakul, Ponlapat Rojnuckarin

{"title":"Five decades of successive establishment of hemophilia care in Thailand.","authors":"Ampaiwan Chuansumrit, Thip Sriphaisal, Triroj Krutvecho, Nongnuch Sirachainan, Pimpun Kitpoka, Monratta Pitakcharoen, Suphaneewan Jaovisidha, Panyu Panburana, Monthon Suwannuraks, Nantana Sri-Udomporn, Chusak Kijkunasathian, Rungrote Nateserinilkul, Bunchoo Pongtanakul, Chanchai Traivaree, Patcharee Komvilaisak, Darintr Sosothikul, Yujinda Lektrakul, Thunyakorn Nuntiyagul, Pacharapan Surapolchai, Natsaruth Songthawee, Ekawat Suwantaroj, Pantep Angchaisuksiri, Theera Ruchutrakul, Ponlapat Rojnuckarin","doi":"10.1080/17474086.2025.2486378","DOIUrl":"10.1080/17474086.2025.2486378","url":null,"abstract":"Introduction: Management of patients with hemophilia in healthcare resource limited countries is challenging for healthcare providers.Area covered: Thai patients with hemophilia initially received episodic treatment of cryoprecipitate and fresh frozen plasma (FFP) in 1965. Home treatment using cryoprecipitate at early bleeding episodes was initiated in 1979 and replaced with fresh dry plasma in 1982. Heat-treated, lyophilized cryoprecipitate commenced in 1997, and factor concentrate was imported for clinical use in 2000. A healthy diet, limit weight gain and exercise for the prominent vein constitute a commitment among every hemophiliac. National advocacy of home treatment using factor concentrates at early bleeding episodes started in 2006 and nationwide low-dose prophylaxis in 2018. Immune tolerance induction (ITI) was initially attempted in 1997. The dental splint was invented as a local measure for dental procedures in 1979, and fibrin glue has been applied to surgical sites. A computerized program for hereditary bleeding disorders registry was initiated in 1999 and became nationwide in 2020. Finally, nationwide nonfactor therapy of monthly low-dose emicizumab prophylaxis will be established soon.Expert opinion: Hemophilia care in Thailand constitutes the real-world experience passing from generation to generation for five decades using our limited resources efficiently.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"309-321"},"PeriodicalIF":2.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0